A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis

Younossi, Zobair M.; Page, Sandra; Rafiq, Nila; Birerdinc, Aybike; Stepanova, Maria; Hossain, Noreen; Afendy, Arian; Younoszai, Zahra; Goodman, Zachary; Baranova, Ancha

doi:10.1007/s11695-010-0204-1

Cited by 141 publications

(115 citation statements)

References 38 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…In other reports, TIMP-1 levels have been included in non-invasive algorithms to classify the extent of fibrosis (36,37). In support of such a role, animal models have shown that TIMP-1 overexpression promotes liver fibrosis (12) and retards fibrosis resolution (13), and the administration of TIMP-1 blocking antibodies attenuates fibrosis (38).…”

Section: Discussionmentioning

confidence: 99%

Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion

Ramezani-Moghadam

Wang

et al. 2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Adiponectin has been shown to limit liver fibrosis, but the molecular mechanisms remain unknown. Results: In vitro and in vivo adiponectin increases TIMP-1 secretion, which binds to the CD63/␤1-integrin complex to decrease FAK activity and stellate cell migration. Conclusion: Adiponectin-promoted TIMP-1 plays an important role in limiting liver fibrosis. Significance: Targeting adiponectin signaling could be a useful way to limit liver fibrosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion

Ramezani-Moghadam

Wang

et al. 2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…As clearly demonstrated by Bedossa et al, liver biopsy sampling variability is especially prominent in the cases of discriminating stages of fibrosis [1]. In fact, the METAVIR scoring system which was used for staging fibrosis on a typical 15-mm liver biopsy core was correct approximately 65% of the times, reflecting an AUC of only 0.82 [1]. Because of this relatively low performance, using core liver biopsy as a "gold standard" for validating non-invasive biomarkers is difficult at best.…”

Section: Replymentioning

confidence: 91%

“…We are fully aware of these drawbacks, especially those related to the performance of a biomarker panel in comparison to tests containing only a single biomarker. It is important to note that some of the variables included in a panel of biomarker such as ours (presence of diabetes, gender, BMI, triglycerides, and AST) are routinely available in clinical practice [1]. Therefore, adding these parameters to a "biomarker panel" should not increase the associated costs.…”

Section: Replymentioning

confidence: 99%

“…It is important to bear in mind that the biopsy itself has an area under the curve (AUC), which could be derived from the "true gold standard" using an entire section of the liver [2]. As clearly demonstrated by Bedossa et al, liver biopsy sampling variability is especially prominent in the cases of discriminating stages of fibrosis [1]. In fact, the METAVIR scoring system which was used for staging fibrosis on a typical 15-mm liver biopsy core was correct approximately 65% of the times, reflecting an AUC of only 0.82 [1].…”

Section: Replymentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for Non-invasive Diagnosis of Non-alcoholic Steatohepatitis

Baranova

Younossi

2011

OBES SURG

Self Cite

View full text Add to dashboard Cite

“…A kaszpáz 3 aktivációja során a citokeratin 18 (CK18) hasítása követ-kezik be, amely egy átmeneti fi lamentum a májsejtekben. Az ebből létrejövő CK18-M30 részlet (fragmentum) koncentrációja jól korrelál a NASH súlyosságával számos vizsgálat alapján [40,41,42], ugyanúgy, mint a CK18-M65 szintje (AUROC: 0,8) [32].…”

Section: A Steatosis Progressziójának Markereiunclassified

Non-invasive assessment of fatty liver

2015

View full text Add to dashboard Cite

A májat érő különböző károsító hatások miatt (fertőző ágensek, anyagcserezavarok, nem megfelelő táplálkozás, elhí-zás, toxikus ártalmak, autoimmun folyamatok) kóros májműködés, májkárosodás jön létre, amely a máj elzsírosodá-sához, illetve kötőszövetes átépüléséhez vezethet. A májműködés zavarainak leggyakoribb okai a hepatitis B-és Cvírusok, az alkoholfogyasztás, illetve a nem alkoholos zsírmájbetegség. Napjainkban a májbetegségek kórisméjének arany standardja a szövettani vizsgálat. A májbiopszia veszélyei és szövődményei miatt azonban világszerte nagy az igény olyan, nem invazív jelzőmolekulák, pontrendszerek kidolgozására, képalkotó eljárások fejlesztésére, amelyek az elzsírosodás mértékét, illetve későbbiekben a betegség lefolyását, a gyulladásos aktivitást és a fi brosis fokát is jól jelzik. A szerzők összefoglaló közleményükben áttekintik a májelzsírosodás nem invazív jellemzésének lehetőségeit. Bemutatják a próbák mutatóit (pozitív, negatív prediktív érték, érzékenység, fajlagosság). Kitérnek a képalkotó eljárások klinikai alkalmazásaira is. Az ismertetett módszerek közül több hasznos, nem invazív eljárás a steatosis értékelésében, a betegség lefolyásának és a terápiás válasz nyomon követésében, de pontos megítélésükre további vizsgálatok szük-ségesek. Orv. Hetil., 2015, 156(14), 543-551. Kulcsszavak: májelzsírosodás, steatosis hepatis, nem invazív próbák, képalkotó eljárások Non-invasive assessment of fatty liverAs the result of various harmful effects (infectious agents, metabolic diseases, unhealthy diet, obesity, toxic agents, autoimmune processes) hepatic damage may develop, which can progress towards liver steatosis, and fi brosis as well. The most common etiological factors of liver damages are hepatitis B and C infection, alcohol consumption and nonalcoholic fatty liver disease. Liver biopsy is considered as the gold standard for the diagnosis of chronic liver diseases. Due to the dangers and complications of liver biopsy, studies are focused on non-invasive markers and radiological imaging for liver steatosis, progression of fatty liver, activity of the necroinfl ammation and the severity of the fi brosis. Authors review the possibilities of non-invasive assessment of liver steatosis. The statistical features of the probes (positive, negative predictive values, sensitivity, specifi city) are reviewed. The role of radiological imaging is also discussed. Although the non-invasive methods discussed in this article are useful to assess liver steatosis, further studies are needed to validate to follow progression of the diseases and to control therapeutic response. Keywords: liver steatosis, fatty liver, non-invasive methods, radiological imagingEgresi, A., Lengyel, G., Hagymási, K. [Non-invasive assessment of fatty liver]. Orv. Hetil., 2015, 156(14), 543-551. ÖSSZEFOGLALÓ KÖZLEMÉNYRövidítések AFLD = alkoholos zsírmájbetegség; AGA = American Gastroenterological Association; ALP = alkalikus foszfatáz; ALT = alanin-aminotranszferáz; AST = aszpartát-aminotranszferáz; ATP = adenozin-trifoszfát; BMI = t...

show abstract

A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis

Abstract: This NAFLD Diagnostic Panel based on a clinical and laboratory data has good performance characteristics and is easy to use. This biomarker panel could become useful in the management of patients with NAFLD.

Cited by 141 publications

References 38 publications

Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion

Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion

Biomarkers for Non-invasive Diagnosis of Non-alcoholic Steatohepatitis

Non-invasive assessment of fatty liver

Contact Info

Product

Resources

About